Online seminar on Payer Contracts, HTA process and Tender management
Webcode 24042202
Dr. Thomas Ecker
Ecker + Ecker GmbH, Hamburg
CEO;
Thomas Ecker is CEO of Ecker + Ecker. Since 2004 he has focused on HTA, Pricing and Reimbursement of pharmaceuticals. In that role he has been responsible for more than 100 G-BA submissions and price negotiations. His current focus is on EU HTA strategy and dossier development.
More information please click here.
Graham Foxon Ph.D. MBA
Remap Consulting UK Ltd, Cheshire, GREAT BRITAIN
Managing Director Graham co-founded Remap Consulting in 2014 with the mission to help clients optimise their pricing, health economics and market access outcomes. With over 20 years pharmceutical experience Graham brings unparalleled expertise in developing global product launch strategies and producing HTA submissions to adress payers' pricing and reimbursement requirements.
Dr Alicia Gil
OMAKASE Consulting S.L., Barcelona
CEO
Fabio Kistner
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Manager; Fabio Kistner is a Manager in the Life Science Division of Simon-Kucher & Partners in Munich, Germany Since joining Simon-Kucher, Fabio has worked on a variety of global and Germany-based pricing & market access projects in the pharmaceuticals and biotechnology sector as well as in the digital health space, incl. the development of international P&MA strategies, negotiation strategies, and portfolio development and contracting strategies Fabio has worked on 30+ multinational projects for several major life science clients across a wide variety of therapeutic areas including oncology, (ultra) orphan diseases, cell & gene therapies and chronic diseases
Dr Entela Xoxi
Research fellow at Università Cattolica del Sacro Cuore - School of Health Economics and Management (ALTEMS):
Pharmaceutical Scientific Advisor, Research consultant at UCSC with tasks on EUnetHTA JA3 WP5 and HTA WP6 & WP10, from 2013 - 2016: AIFA’s Registries Co-ordinator
22-23/04/2024
22-23/04/2024
22 April 2024: 9:00 am - 3:00 pm23 A...
22 April 2024: 9:00 am - 3:00 pm
23 April 2024: 9:00 am - 3:00 pm
online
online
Veranstaltung - 1,590 € zzgl. MwSt.
The participation fee includes downloadable documentation, a certificate, access to the Learning Space and technical support including PreMeeting.
Veranstaltung - 1,590 € zzgl. MwSt.
The participation fee includes downloadable documentation, a certificate, access to the Learning Space and technical support including PreMeeting.
Leila Grupp
Conference Manager
+49 6221 500-695
l.grupp@forum-institut.de
Online seminar on Market Access & Pricing in Europe - this is how you can gain access as a pharmaceutical manufacturer!
Market access and pricing for drugs is complex and requires careful preparation for launch. Knowledge of the underlying health systems and the different, mutually influencing pricing systems in Europe is essential for it.
In our online seminar you will receive the most important information for successful market access in the EU4 countries and in the UK.
22 April 2024: Payer archetypes, Market Access and Pricing in France and the UK
23 April 2024: Market Access and Pricing in Spain, Germany and Italy
By attending the seminar...
09:00 Introduction
09:15
Fabio Kistner
10:15 break
10:30
Graham Foxon
12:15 Lunch break
13:15
Graham Foxon
15:00 End of day 1
09:00 Start of day 2
09:00
Dr. Alicia Gil
10:45 break
11:00
Mariangela Prada
12:30 Lunch break
13:30
Dr. Thomas Ecker
15:00 End of seminar
Overall score of all evaluations in 2022
Five stars on Trustpilot = Excellent
This webcast combines the work of the HTA coordination group with the national preparation for the EU-HTA in the Nordic ...
Learn the essentials of the MDR and how to navigate around the legislation and to apply it.
FDA inspection readiness: Gain the knowledge and skills necessary to manage future FDA inspections with confidence and e...
Online Seminar about Generic Drugs: Market Access and Pricing in Europe
This webcast covers HTA procedures and alignment with the EU-HTA processes in France, Italy, Spain and UK
Get a first insight into generic market access and pricing in Europe.
Details
